公开(公告)号：IL256043A

公开(公告)日：2020-05-31

申请号：IL25604317

申请日：2017-12-01

Applicant: ABBVIE INC ,  ARGIRIADI MARIA A ,  BREINLINGER ERIC C ,  CUSACK KEVIN P ,  HOBSON ADRIAN D ,  POTIN DOMINIQUE ,  BARTH MARTINE ,  AMAUDRUT JEROME ,  POUPARDIN OLIVIA ,  MOUNIER LAURENT ,  KORT MICHAEL E

Inventor： ARGIRIADI MARIA A ,  BREINLINGER ERIC C ,  CUSACK KEVIN P ,  HOBSON ADRIAN D ,  POTIN DOMINIQUE ,  BARTH MARTINE ,  AMAUDRUT JEROME ,  POUPARDIN OLIVIA ,  MOUNIER LAURENT ,  KORT MICHAEL E

Abstract: The invention provides compounds of the following formula, pharmaceutically acceptable salts thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

公开(公告)号：IL256043D0

公开(公告)日：2018-01-31

申请号：IL25604317

申请日：2017-12-01

Applicant: ABBVIE INC ,  ARGIRIADI MARIA A ,  BREINLINGER ERIC C ,  CUSACK KEVIN P ,  HOBSON ADRIAN D ,  POTIN DOMINIQUE ,  BARTH MARTINE ,  AMAUDRUT JEROME ,  POUPARDIN OLIVIA ,  MOUNIER LAURENT ,  KORT MICHAEL E

Inventor： ARGIRIADI MARIA A ,  BREINLINGER ERIC C ,  CUSACK KEVIN P ,  HOBSON ADRIAN D ,  POTIN DOMINIQUE ,  BARTH MARTINE ,  AMAUDRUT JEROME ,  POUPARDIN OLIVIA ,  MOUNIER LAURENT ,  KORT MICHAEL E

IPC: C07D20060101

Abstract: The invention provides compounds of the following formula, pharmaceutically acceptable salts thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

公开(公告)号：IL274537D0

公开(公告)日：2020-06-30

申请号：IL27453720

申请日：2020-05-08

Applicant: ABBVIE INC ,  ARGIRIADI MARIA A ,  BREINLINGER ERIC C ,  CUSACK KEVIN P ,  HOBSON ADRIAN D ,  POTIN DOMINIQUE ,  BARTH MARTINE ,  AMAUDRUT JEROME ,  POUPARDIN OLIVIA ,  MOUNIER LAURENT ,  KORT MICHAEL E

Inventor： ARGIRIADI MARIA A ,  BREINLINGER ERIC C ,  CUSACK KEVIN P ,  HOBSON ADRIAN D ,  POTIN DOMINIQUE ,  BARTH MARTINE ,  AMAUDRUT JEROME ,  POUPARDIN OLIVIA ,  MOUNIER LAURENT ,  KORT MICHAEL E

IPC: A61P1/00 ,  A61P1/04 ,  A61P13/12 ,  A61P17/00 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00

Abstract: The invention provides compounds of the following formula, pharmaceutically acceptable salts thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

公开(公告)号：WO2012019315A1

公开(公告)日：2012-02-16

申请号：PCT/CN2010/001213

申请日：2010-08-10

Applicant: ABBOTT LABORATORIES ,  ABBOTT LABORATORIES TRADING (SHANGHAI) COMPANY, LTD ,  BAYBURT, Erol, K. ,  CLAPHAM, Bruce ,  COX, Phil, B. ,  DAANEN, Jerome, F. ,  GOMTSYAN, Arthur ,  KORT, Michael, E. ,  KYM, Philip, R. ,  VOIGHT, Eric, A.

Inventor： BAYBURT, Erol, K. ,  CLAPHAM, Bruce ,  COX, Phil, B. ,  DAANEN, Jerome, F. ,  GOMTSYAN, Arthur ,  KORT, Michael, E. ,  KYM, Philip, R. ,  VOIGHT, Eric, A.

IPC: C07D213/30 ,  C07D239/26 ,  C07D405/06 ,  C07D405/08 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/505 ,  A61P25/00 ,  A61P29/00

CPC classification number: C07D213/30 ,  C07D213/50 ,  C07D239/26 ,  C07D401/12 ,  C07D405/12

Abstract: Disclosed herein are modulators of TRPV3 of formula (I), wherein G 1 , X 1 , X 2 , X 3 , X 4 , X 5 , G 2 , Z 1 , R a , R b , u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb，u和p如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。

公开(公告)号：WO2009055749A1

公开(公告)日：2009-04-30

申请号：PCT/US2008/081229

申请日：2008-10-25

Applicant: ABBOTT LABORATORIES ,  PERNER, Richard J. ,  KOENIG, John R. ,  DIDOMENICO, Stanley, Jr. ,  BAYBURT, Erol, K. ,  DAANEN, Jerome, F. ,  GOMTSYAN, Arthur, R. ,  KORT, Michael E. ,  KYM, Philip R. ,  VASUDEVAN, Anil ,  SCHMIDT, Robert, G. ,  VOIGHT, Eric

Inventor： PERNER, Richard J. ,  KOENIG, John R. ,  DIDOMENICO, Stanley, Jr. ,  BAYBURT, Erol, K. ,  DAANEN, Jerome, F. ,  GOMTSYAN, Arthur, R. ,  KORT, Michael E. ,  KYM, Philip R. ,  VASUDEVAN, Anil ,  SCHMIDT, Robert, G. ,  VOIGHT, Eric

IPC: C07D263/48 ,  C07D413/04 ,  C07D413/12 ,  A61K31/421 ,  A61P29/00

CPC classification number: C07D413/12 ,  C07D263/48 ,  C07D413/04

Abstract: Compounds of formula (I) wherein R 1 , R 2 , R 4 , and W are defined in the description are TRPV1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 在描述中定义R1，R2，R4和W的式（I）化合物是具有CNS穿透的TRPV1拮抗剂。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：WO2006086229A1

公开(公告)日：2006-08-17

申请号：PCT/US2006/003865

申请日：2006-02-03

Applicant: ABBOTT LABORATORIES ,  PEREZ-MEDRANO, Arturo ,  NELSON, Derek, W. ,  CARROLL, William, A. ,  KORT, Michael, E. ,  GREGG, Robert, J. ,  VOIGHT, Eric, A. ,  JARVIS, Michael, F. ,  KOWALUK, Elizabeth, A.

Inventor： PEREZ-MEDRANO, Arturo ,  NELSON, Derek, W. ,  CARROLL, William, A. ,  KORT, Michael, E. ,  GREGG, Robert, J. ,  VOIGHT, Eric, A. ,  JARVIS, Michael, F. ,  KOWALUK, Elizabeth, A.

IPC: A61K31/381 ,  A61P25/00 ,  A61P29/00

CPC classification number: A61K31/381 ,  A61K31/41 ,  A61K31/4439

Abstract: The present invention relates to the use of selective P2X 7 receptor antagonists of formula (I), or a pharmaceutically acceptable salt or prodrug thereof wherein D, R 1 and R 2 are as defined in claim 1, for the treatment of neuropathic pain, chronic inflammatory pain, inflammation, neurodegeneration and for promoting neuroregeneration.

Abstract translation: 本发明涉及式（I）的选择性P2X 7受体拮抗剂或其药学上可接受的盐或前药，其中D，R 1和R 2 > 2 如权利要求1中所定义，用于治疗神经性疼痛，慢性炎性疼痛，炎症，神经变性和促进神经再生。

公开(公告)号：WO2004099154A3

公开(公告)日：2005-04-14

申请号：PCT/US2004013530

申请日：2004-04-29

Applicant: ABBOTT LAB ,  ATKINSON ROBERT N ,  DRIZEN IRENE ,  GREGG ROBERT J ,  GROSS MICHAEL F ,  KORT MICHAEL E ,  SHI LEI

Inventor： ATKINSON ROBERT N ,  DRIZEN IRENE ,  GREGG ROBERT J ,  GROSS MICHAEL F ,  KORT MICHAEL E ,  SHI LEI

IPC: A61K31/416 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D231/24 ,  C07D401/04 ,  C07D401/12 ,  A61K31/415

CPC classification number: C07D401/04 ,  A61K31/416 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D231/24 ,  C07D401/12

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, wherein R1 is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heteroaryl, or heteroarylalkyl; R4 is formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie) or formula (If); or formula (II), or a pharmaceutically acceptable salt, amide, ester or prodrug thereof, wherein R14 is formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI), or formula (XII); modulate PN3 in mammals and are useful in treating pain in mammals.

Abstract translation: 式（I）化合物或其药学上可接受的盐，酰胺，酯或前药，其中R 1是烷基，芳基，芳基烷基，环烷基，环烷基烷基，卤代烷基，杂环，杂环烷基，杂芳基或杂芳基烷基; R4是式（Ia），式（Ib），式（Ic），式（Id），式（Ie）或式（If）; 或其药学上可接受的盐，酰胺，酯或前药，其中R 14为式（III），式（IV），式（V），式（VI），式（Ⅶ），式 ），式（IX），式（X），式（XI）或式（XII）; 调节哺乳动物中的PN3，可用于治疗哺乳动物的疼痛。

公开(公告)号：WO2021127586A1

公开(公告)日：2021-06-24

申请号：PCT/US2020/066243

申请日：2020-12-18

Applicant: CALICO LIFE SCIENCES LLC ,  ABBVIE INC. ,  VEITS, Gesine Kerstin ,  FITZGERALD, Mark E. ,  HIRD, Alexander W. ,  HENDERSON, James A. ,  VORA, Harit U. ,  SWEIS, Ramzi F. ,  KORT, Michael E. ,  NASVESCHUK, Christopher G. ,  DUPLESSIS, Martin

Inventor： VEITS, Gesine Kerstin ,  FITZGERALD, Mark E. ,  HIRD, Alexander W. ,  HENDERSON, James A. ,  VORA, Harit U. ,  SWEIS, Ramzi F. ,  NASVESCHUK, Christopher G. ,  DUPLESSIS, Martin

IPC: C07D417/12 ,  C07D417/14 ,  C07D471/10 ,  A61P3/00 ,  A61P35/00 ,  A61K47/00 ,  A61K31/4523 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4545 ,  A61K9/0019

Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

公开(公告)号：WO2012129491A1

公开(公告)日：2012-09-27

申请号：PCT/US2012/030317

申请日：2012-03-23

Applicant: ABBOTT LABORATORIES ,  CLAPHAM, Bruce ,  COX, Philip, B. ,  DART, Michael, J. ,  GOMTSYAN, Arthur ,  JINKERSON, Tammie, K. ,  KEDDY, Ryan, G. ,  KORT, Michael, E. ,  KYM, Philip, R. ,  MATULENKO, Mark ,  SCHMIDT, Robert, G., Jr. ,  VILLAMIL, Clara, I. ,  VOIGHT, Eric, A. ,  WOLLER, Kevin, R.

Inventor： CLAPHAM, Bruce ,  COX, Philip, B. ,  DART, Michael, J. ,  GOMTSYAN, Arthur ,  JINKERSON, Tammie, K. ,  KEDDY, Ryan, G. ,  KORT, Michael, E. ,  KYM, Philip, R. ,  MATULENKO, Mark ,  SCHMIDT, Robert, G., Jr. ,  VILLAMIL, Clara, I. ,  VOIGHT, Eric, A. ,  WOLLER, Kevin, R.

IPC: C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  A61K31/44 ,  A61K31/505 ,  C07D211/06 ,  C07D239/28 ,  C07D239/30 ,  A61P25/00

CPC classification number: C07D213/61 ,  A61K31/44 ,  A61K31/505 ,  C07D211/06 ,  C07D213/38 ,  C07D213/64 ,  C07D213/643 ,  C07D213/74 ,  C07D239/26 ,  C07D239/28 ,  C07D239/30 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/10 ,  C07D417/12

Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein X 1 , X 2 , R 1 , R 2 , R x , and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中X1，X2，R1，R2，Rx和n如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。

公开(公告)号：WO2010045402A1

公开(公告)日：2010-04-22

申请号：PCT/US2009/060734

申请日：2009-10-15

Applicant: ABBOTT LABORATORIES ,  GOMTSYAN, Arthur R. ,  VOIGHT, Eric A. ,  BAYBURT, Erol K. ,  CHEN, Jun ,  DAANEN, Jerome F. ,  DIDOMENICO, Stanley, Jr. ,  KORT, Michael E. ,  KYM, Philip R. ,  MCDONALD, Heath A. ,  PERNER, Richard J. ,  SCHMIDT, Robert G.

Inventor： GOMTSYAN, Arthur R. ,  VOIGHT, Eric A. ,  BAYBURT, Erol K. ,  CHEN, Jun ,  DAANEN, Jerome F. ,  DIDOMENICO, Stanley, Jr. ,  KORT, Michael E. ,  KYM, Philip R. ,  MCDONALD, Heath A. ,  PERNER, Richard J. ,  SCHMIDT, Robert G.

IPC: C07D311/74 ,  C07D405/12 ,  A61K31/33 ,  A61P19/02

CPC classification number: C07D405/12 ,  C07D311/74

Abstract: Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，溶剂合物，前药，前药盐或其组合，其中R1，R2，R3，R4和m在说明书中定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。